Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Provention Bio stock

Own Provention Bio stock in just a few minutes.

Provention Bio, Inc is a biotechnology business based in the US. Provention Bio shares (PRVB) are listed on the NASDAQ and all prices are listed in US Dollars. Provention Bio employs 59 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Provention Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRVB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Provention Bio share price

Use our graph to track the performance of PRVB stocks over time.

Provention Bio shares at a glance

Information last updated 2021-04-23.
52-week range$7.54 - $19.19
50-day moving average $10.67
200-day moving average $13.92
Wall St. target price$18.36
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.94

Buy Provention Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Provention Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Provention Bio financials

Gross profit TTM $0
Return on assets TTM -58.09%
Return on equity TTM -102.04%
Profit margin 0%
Book value $1.97
Market capitalisation $501.4 million

TTM: trailing 12 months

Shorting Provention Bio shares

There are currently 3.8 million Provention Bio shares held short by investors – that's known as Provention Bio's "short interest". This figure is 35% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting Provention Bio shares can be evaluated.

Provention Bio's "short interest ratio" (SIR)

Provention Bio's "short interest ratio" (SIR) is the quantity of Provention Bio shares currently shorted divided by the average quantity of Provention Bio shares traded daily (recently around 940198.27586207). Provention Bio's SIR currently stands at 4.06. In other words for every 100,000 Provention Bio shares traded daily on the market, roughly 4060 shares are currently held short.

However Provention Bio's short interest can also be evaluated against the total number of Provention Bio shares, or, against the total number of tradable Provention Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Provention Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Provention Bio shares in existence, roughly 60 shares are currently held short) or 0.0657% of the tradable shares (for every 100,000 tradable Provention Bio shares, roughly 66 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Provention Bio.

Find out more about how you can short Provention Bio stock.

Provention Bio share dividends

We're not expecting Provention Bio to pay a dividend over the next 12 months.

Provention Bio share price volatility

Over the last 12 months, Provention Bio's shares have ranged in value from as little as $7.54 up to $19.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Provention Bio's is 3.2487. This would suggest that Provention Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Provention Bio overview

Provention Bio, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. , Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site